These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 33101207)

  • 1. Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science.
    Zhang S; Wong YT; Tang KY; Kwan HY; Su T
    Front Endocrinol (Lausanne); 2020; 11():572729. PubMed ID: 33101207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Si Miao Formula attenuates non-alcoholic fatty liver disease by modulating hepatic lipid metabolism and gut microbiota.
    Han R; Qiu H; Zhong J; Zheng N; Li B; Hong Y; Ma J; Wu G; Chen L; Sheng L; Li H
    Phytomedicine; 2021 May; 85():153544. PubMed ID: 33773192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multi-targeting therapeutic mechanisms of the Chinese herbal medicine QHD in the treatment of non-alcoholic fatty liver disease.
    Feng Q; Liu W; Baker SS; Li H; Chen C; Liu Q; Tang S; Guan L; Tsompana M; Kozielski R; Baker RD; Peng J; Liu P; Zhu R; Hu Y; Zhu L
    Oncotarget; 2017 Apr; 8(17):27820-27838. PubMed ID: 28416740
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory effect of a Chinese herbal medicine formula on non-alcoholic fatty liver disease.
    Yang JM; Sun Y; Wang M; Zhang XL; Zhang SJ; Gao YS; Chen L; Wu MY; Zhou L; Zhou YM; Wang Y; Zheng FJ; Li YH
    World J Gastroenterol; 2019 Sep; 25(34):5105-5119. PubMed ID: 31558860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Traditional Chinese herbal extracts inducing autophagy as a novel approach in therapy of nonalcoholic fatty liver disease.
    Liu C; Liao JZ; Li PY
    World J Gastroenterol; 2017 Mar; 23(11):1964-1973. PubMed ID: 28373762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.
    Zhou H; Ma C; Wang C; Gong L; Zhang Y; Li Y
    Eur J Pharmacol; 2021 May; 898():173976. PubMed ID: 33639194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDG, an Ophiopogon japonicus polysaccharide, inhibits non-alcoholic fatty liver disease by regulating the abundance of Akkermansia muciniphila.
    Zhang L; Wang Y; Wu F; Wang X; Feng Y; Wang Y
    Int J Biol Macromol; 2022 Jan; 196():23-34. PubMed ID: 34920070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
    Zhang Y; Tang K; Deng Y; Chen R; Liang S; Xie H; He Y; Chen Y; Yang Q
    Biomed Pharmacother; 2018 Jun; 102():1025-1036. PubMed ID: 29710519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Liver-gut" axis: A target of traditional Chinese medicine for the treatment of non-alcoholic fatty liver disease.
    Guo K; Xu S; Zeng Z
    Front Endocrinol (Lausanne); 2022; 13():1050709. PubMed ID: 36531498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Herbal medicines and nonalcoholic fatty liver disease.
    Yao H; Qiao YJ; Zhao YL; Tao XF; Xu LN; Yin LH; Qi Y; Peng JY
    World J Gastroenterol; 2016 Aug; 22(30):6890-905. PubMed ID: 27570425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural modulation of gut microbiota during alleviation of non-alcoholic fatty liver disease with Gynostemma pentaphyllum in rats.
    Shen SH; Zhong TY; Peng C; Fang J; Lv B
    BMC Complement Med Ther; 2020 Feb; 20(1):34. PubMed ID: 32024509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese herbal medicines: The modulator of nonalcoholic fatty liver disease targeting oxidative stress.
    Gong P; Long H; Guo Y; Wang Z; Yao W; Wang J; Yang W; Li N; Xie J; Chen F
    J Ethnopharmacol; 2024 Jan; 318(Pt B):116927. PubMed ID: 37532073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Daesiho-tang on obesity with non-alcoholic fatty liver disease: a study protocol for a randomised, double-blind, placebo-controlled pilot trial.
    Han K; Kwon O; Park HJ; Jung SY; Yang C; Son CG
    Trials; 2020 Jan; 21(1):128. PubMed ID: 32005283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Gut Microbiota for the Treatment of Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Bandsma R
    Curr Drug Targets; 2015; 16(12):1324-31. PubMed ID: 25882223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of herbs and active ingredients ameliorate non-alcoholic fatty liver disease under the guidance of traditional Chinese medicine.
    Zhou Z; Zhang J; You L; Wang T; Wang K; Wang L; Kong X; Gao Y; Sun X
    Front Endocrinol (Lausanne); 2022; 13():1000727. PubMed ID: 36204095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
    Ni Y; Ni L; Zhuge F; Fu Z
    Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polysaccharide from
    Li L; Lan X; Peng X; Shi S; Zhao Y; Liu W; Luo Q; Jia L; Feng B; Chen Z; Zou Y; Huang C
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effect of quercetin on high-fat diet-induced non-alcoholic fatty liver disease in mice is mediated by modulating intestinal microbiota imbalance and related gut-liver axis activation.
    Porras D; Nistal E; Martínez-Flórez S; Pisonero-Vaquero S; Olcoz JL; Jover R; González-Gallego J; García-Mediavilla MV; Sánchez-Campos S
    Free Radic Biol Med; 2017 Jan; 102():188-202. PubMed ID: 27890642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Active Compounds from Plant Food and Chinese Herbal Medicine for Nonalcoholic Fatty Liver Disease.
    Liu Q; Zhu L; Cheng C; Hu YY; Feng Q
    Curr Pharm Des; 2017; 23(34):5136-5162. PubMed ID: 28925892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD).
    Thondam SK; Cuthbertson DJ; Wilding JPH
    Peptides; 2020 Mar; 125():170208. PubMed ID: 31759125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.